ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Clinical Trial Governance A Strategic Look At KPIs From An RTSM Perspective

  Learn how data-driven metrics improve oversight, mitigate risk, and accelerate execution while safeguarding supply continuity and patient safety.

• How AI And ML Can Transform Clinical Trial Conduct

  There’s no doubt that 2023 will be remembered as the year that artificial intelligence and machine learning became mainstream. Gain an overview of the uses of AI and ML in clinical conduct.

• RTSM Automating Adaptive Enrollment In Basket Trials

  Adaptive basket trials need real-time data to close underperforming cohorts fast. See how automation closes that gap and protects patients.

• Trends Shaping The Pharmaceutical Industry's Future

  Decentralized trials and patient choice are key to expanding study reach. Here, we examine how patient access increases with diverse options and AI-powered connections across health systems and sites.

• Protocol Amendments And Electronic Consent: Overcoming The Challenges To Reap The Benefits

  Learn about some insights that have been gleaned from experience deploying eConsent on diverse trial types around the world.

• Bringing Clinical Research To The Patient Using Patient-Centric Tech

  By fostering daily interactions between patients and technology, these smart hubs offer a sustainable approach to ensuring the success and integrity of clinical trials in an evolving landscape of drug development.

• Remote Clinical Trial Monitoring: CRA Success In An Era Of Autonomy

  As organizations become more skillful in training and monitoring CRAs, the latter can be empowered with greater flexibility and freedom in scheduling and travel.

• Key Insights From The FDA's DHT Guidance

  Check out a summary of the FDA’s guidance Framework for the Use of DHTs in Clinical Trials and what it means for sponsors and investigators using these innovative tools.

• Consolidating Access Into A Single Platform: A Site CEO's Perspective

  By providing research sites with a unified, streamlined interface, we can reduce operational friction, enhance collaboration, and ultimately accelerate the development of new therapies.

• Clinical Trials In The Age Of Cost Caps

  On February 7, 2025, the NIH introduced a pivotal policy (NOT-OD-25-068), capping indirect cost recovery at 15% for research grants.